Trial Profile
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Bicalutamide; Flutamide; Nilutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ENZAMET
- 27 Jan 2024 Results retrospectively analyzing Radiographic progression without PSA progression in metastatic hormone-sensitive prostate , presented at the 2024 Genitourinary Cancers Symposium
- 24 Oct 2023 Results of post-hoc analysis assessing the efficacy of enzalutamide in patients with metastatic hormone-sensitive prostate cancer greater than equal to 70yrs versus less than 70yrs of age, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Results of meta analysis from ARASENS, PEACE-1, ENZAMET, presented at the 59th Annual Meeting of the American Society of Clinical Oncology